Non-Invasive Prenatal Testing 2.02.25
Summary
Excellus BlueCross BlueShield policy 2.02.25 finds non-invasive prenatal testing (NIPT) medically appropriate to screen for trisomy 21, 13 and 18 in singleton pregnancies, and finds NIPT for twin zygosity not medically necessary. The policy lists NIPT as investigational for multiple gestations, other aneuploidies, microdeletions, fetal sex chromosome aneuploidy, single-gene disorders, rolling circle replication screening, fetal nasal bone measurement and fetal RhD genotyping. A policy edit dated 05/13/26 removed Vasistera as an example for single-gene disorder testing and states that Vasistera is a limited NIPT for common chromosomal aneuploidies that is investigational.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.